FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Morrow

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Marc P Bonaca; Henri Bounameaux; Eugene Braunwald; Mark A Creager; Mikael Dellborg; Jessica M Lamp; Sabina A Murphy; Jeffrey Olin; Benjamin M Scirica; David A Morrow
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
David A Morrow; Sabina A Murphy; Benjamin M Scirica; Mark J Alberts; Sebastian F Ameriso; Marc P Bonaca; Eugene Braunwald; Shinya Goto; Graeme J Hankey; Jay P Mohr
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Dylan L Steen; Christopher P Cannon; Suhas S Lele; Banibrata Mukhopadhyay; Sabina A Murphy; Mohan M Rajapurkar; Benjamin M Scirica; David A Morrow
Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Morrow (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marc P Bonaca; Henri Bounameaux; Eugene Braunwald; Mark A Creager; Mikael Dellborg; Jessica M Lamp; Sabina A Murphy; Jeffrey Olin; Benjamin M Scirica; David A Morrow
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Circulation 2013;127(14):1522-9, 1529e1-6.
2013: David A Morrow; Sabina A Murphy; Benjamin M Scirica; Mark J Alberts; Sebastian F Ameriso; Marc P Bonaca; Eugene Braunwald; Shinya Goto; Graeme J Hankey; Jay P Mohr
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Stroke; a journal of cerebral circulation 2013;44(3):691-8.
2013: Dylan L Steen; Christopher P Cannon; Suhas S Lele; Banibrata Mukhopadhyay; Sabina A Murphy; Mohan M Rajapurkar; Benjamin M Scirica; David A Morrow
Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.
Clinical cardiology 2013;36(3):139-45.
2012: Benjamin M Scirica; Michal Tendera; Frans Van de Werf; Robert Wilcox; Marc P Bonaca; Eugene Braunwald; Gaetano M De Ferrari; Daniel Isaza; Basil S Lewis; Felix Mehrhof; Piera A Merlini; David A Morrow; Sabina A Murphy; Marc S Sabatine
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Lancet 2012;380(9850):1317-24.
2012: David A Morrow; Michelle L O'Donoghue
Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis.
Journal of the American College of Cardiology 2012;60(14):1257-8.
2012: Amit N Vora; Marc P Bonaca; Kevin Croce; Petr Jarolim; Sabina Murphy; Christian T Ruff; Marc S Sabatine; Daniel I Simon; David A Morrow
Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain.
Journal of thrombosis and thrombolysis 2012;34(2):229-34.
2012: An H Bui; Christopher P Cannon; Kausik K Ray; Nader Rifai; Marc S Sabatine; Marc P Bonaca; David A Morrow
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Journal of thrombosis and thrombolysis 2012;34(2):222-8.
2012: Marc P Bonaca; Eugene Braunwald; Janna S Chamberlin; Petr Jarolim; Sabina A Murphy; Daniel W Rhodes; Marc S Sabatine; Benjamin M Scirica; PC Southwick; David A Morrow
Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
Journal of the American College of Cardiology 2012;60(4):332-8.
2012: David A Morrow; Sabina A Murphy; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; John Strony; Pierre Theroux; Stephen D Wiviott; Sebastian F Ameriso; Marc P Bonaca; Eugene Braunwald; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu
Vorapaxar in the secondary prevention of atherothrombotic events.
The New England journal of medicine 2012;366(15):1404-13.
2012: Marc P Bonaca; Eugene Braunwald; Sabina A Murphy; Christian T Ruff; Stephen D Wiviott; Elliott M Antman; David A Morrow
American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38).
Circulation 2012;125(4):577-83.
2012: Marc S Sabatine; Sarah Sloan; Scott D Solomon; James A de Lemos; Petr Jarolim; David A Morrow; Torbjorn Omland; Marc A Pfeffer; Eugene Braunwald
Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.
Circulation 2012;125(2):233-40.
2011: Michelle L O'Donoghue; Torbjørn Omland; Sarah Sloan; Scott D Solomon; Alain Tedgui; Joelle Benessiano; Eugene Braunwald; Ziad Mallat; David A Morrow; Marc S Sabatine
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.
Clinical chemistry 2011;57(9):1311-7.
2011: Sean R Wilson; Marc S Sabatine; Stephen D Wiviott; Kausik K Ray; James A de Lemos; Shanggen Zhou; Nader Rifai; Christopher P Cannon; David A Morrow
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22).
American heart journal 2011;161(6):1147-55.e1.
2011: James A de Lemos; David A Morrow; Christopher R deFilippi
Highly sensitive troponin assays and the cardiology community: a love/hate relationship?
Clinical chemistry 2011;57(6):826-9.
2011: Babak Nazer; Kausik K Ray; Sarah Sloan; Benjamin M Scirica; David A Morrow; Christopher P Cannon; Eugene Braunwald
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
European heart journal 2011;32(11):1390-7.
2011: Benjamin M Scirica; Marc S Sabatine; Petr Jarolim; Sabina A Murphy; James L de Lemos; Eugene Braunwald; David A Morrow
Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
European heart journal 2011;32(6):697-705.
2011: Marc P Bonaca; David A Morrow; Eugene Braunwald; Christopher P Cannon; Songtao Jiang; Stephanie Breher; Marc S Sabatine; Tibor Kempf; Lars Wallentin; Kai C Wollert
Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(1):203-10.
2010: James A de Lemos; Mark H Drazner; Torbjorn Omland; Colby R Ayers; Amit Khera; Anand Rohatgi; Ibrahim Hashim; Jarett D Berry; Sandeep R Das; David A Morrow; Darren K McGuire
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.
JAMA : the journal of the American Medical Association 2010;304(22):2503-12.
2010: Willibald Hochholzer; David A Morrow; Robert P Giugliano
Novel biomarkers in cardiovascular disease: update 2010.
American heart journal 2010;160(4):583-94.
2010: Robert P Giugliano; Roberto R Giraldez; David A Morrow; Elliott M Antman; C Michael Gibson; Satishkumar Mohanavelu; Sabina A Murphy; Carolyn H McCabe; Eugene Braunwald
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
European heart journal 2010;31(17):2103-10.
2010: David A Morrow; Elliott M Antman; Keith A A Fox; Harvey D White; Robert P Giugliano; Sabina A Murphy; Carolyn H McCabe; Eugene Braunwald
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
European heart journal 2010;31(17):2097-102.
2010: Benjamin M Scirica; Eugene Braunwald; Luiz Belardinelli; Chester M Hedgepeth; Jindrich Spinar; Whedy Wang; Jie Qin; Ewa Karwatowska-Prokopczuk; Freek W A Verheugt; David A Morrow
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Circulation 2010;122(5):455-62.
2010: Benjamin M Scirica; David A Morrow; Christoph Bode; Witold Ruzyllo; Mikhail Ruda; Anthonius J M Oude Ophuis; Jose Lopez-Sendon; Karl Swedberg; Michal Ogorek; Nader Rifai; Valentina Lukashevich; Mojdeh Maboudian; Christopher P Cannon; Carolyn H McCabe; Eugene Braunwald
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
European heart journal 2010;31(16):1993-2005.
2010: David A Morrow
Cardiovascular risk prediction in patients with stable and unstable coronary heart disease.
Circulation 2010;121(24):2681-91.
2010: Marc Bonaca; Benjamin M Scirica; Marc S Sabatine; Anthony Dalby; Jindrich Spinar; Sabina A Murphy; Petr Jarolim; Eugene Braunwald; David A Morrow
Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.
Journal of the American College of Cardiology 2010;55(19):2118-24.
2010: Jessica L Mega; Judith S Hochman; Benjamin M Scirica; Sabina A Murphy; Sarah Sloan; Carolyn H McCabe; Piera Merlini; David A Morrow
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Circulation 2010;121(16):1809-17.
2010: David A Morrow; Benjamin M Scirica; Marc S Sabatine; James A de Lemos; Sabina A Murphy; Petr Jarolim; Pierre Theroux; Christophe Bode; Eugene Braunwald
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
Journal of the American College of Cardiology 2010;55(12):1189-96.
2010: James R Harkness; Marc S Sabatine; Eugene Braunwald; David A Morrow; Sarah Sloan; Stephen D Wiviott; Robert P Giugliano; Elliott M Antman; Christopher P Cannon; Benjamin M Scirica
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.
American heart journal 2010;159(1):55-62.
2009: Sean R Wilson; Marc S Sabatine; Eugene Braunwald; Sarah Sloan; Sabina A Murphy; David A Morrow
Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial.
American heart journal 2009;158(3):386-91.
2009: David A Morrow; Benjamin M Scirica; Keith A A Fox; Gail Berman; John Strony; Enrico Veltri; Marc P Bonaca; Polly Fish; Carolyn H McCabe; Eugene Braunwald
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
American heart journal 2009;158(3):335-341.e3.
2009: Jessica L Mega; David A Morrow; Alison Brown; Christopher P Cannon; Marc S Sabatine
Identification of genetic variants associated with response to statin therapy.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(9):1310-5.
2009: Roberto R Giraldez; Stephen D Wiviott; José Carlos Nicolau; Satishkumar Mohanavelu; David A Morrow; Elliott M Antman; Robert P Giugliano
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
Drugs 2009;69(11):1433-43.
2009: Jason B Lindsey; James A de Lemos; Francesco Cipollone; Colby R Ayers; Anand Rohatgi; David A Morrow; Amit Khera; Darren K McGuire
Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.
Diabetes care 2009;32(7):1218-20.
2009: David A Morrow; Stephen D Wiviott; Harvey D White; Jose C Nicolau; Ezio Bramucci; Sabina A Murphy; Marc P Bonaca; Christian T Ruff; Benjamin M Scirica; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Circulation 2009;119(21):2758-64.
2009: David A Morrow; Chaim M Brickman; Sabina A Murphy; Kenneth Baran; Ricardo Krakover; Harold Dauerman; Sujatha Kumar; Natanya Slomowitz; Laura Grip; Carolyn H McCabe; Andrew L Salzman
A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.
Journal of thrombosis and thrombolysis 2009;27(4):359-64.
2009: Sean R Wilson; Benjamin M Scirica; Eugene Braunwald; Sabina A Murphy; Ewa Karwatowska-Prokopczuk; Jacqueline Buros; Bernard R Chaitman; David A Morrow
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Journal of the American College of Cardiology 2009;53(17):1510-6.
2009: Benjamin M Scirica; David A Morrow; Andrzej Budaj; Anthony J Dalby; Satishkumar Mohanavelu; Jie Qin; Julian Aroesty; Chester M Hedgepeth; Peter H Stone; Eugene Braunwald
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
Journal of the American College of Cardiology 2009;53(16):1411-21.
2009: David A Morrow; Benjamin M Scirica; Bernard R Chaitman; Darren K McGuire; Sabina A Murphy; Ewa Karwatowska-Prokopczuk; Carolyn H McCabe; Eugene Braunwald
Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Circulation 2009;119(15):2032-9.
2009: Roberto R Giraldez; Marc S Sabatine; David A Morrow; Satishkumar Mohanavelu; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction.
American heart journal 2009;157(3):517-24.
2009: Kausik K Ray; Christopher P Cannon; Richard Cairns; David A Morrow; Paul M Ridker; Eugene Braunwald
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(3):424-30.
2009: Benjamin M Scirica; Christopher P Cannon; Marc S Sabatine; Petr Jarolim; Sarah Sloane; Nader Rifai; Eugene Braunwald; David A Morrow
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
Clinical chemistry 2009;55(2):265-73.
2009: Marc S Sabatine; David A Morrow; James A de Lemos; Petr Jarolim; Eugene Braunwald
Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35.
European heart journal 2009;30(2):162-9.
2008: Shaheeda Ahmed; Christopher P Cannon; Robert P Giugliano; Sabina A Murphy; David A Morrow; Elliott M Antman; Eugene Braunwald; C Michael Gibson
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.
International journal of cardiology 2008;131(1):105-12.
2008: Benjamin A Olenchock; Stephen D Wiviott; Sabina A Murphy; Christopher P Cannon; Nader Rifai; Eugene Braunwald; David A Morrow
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.
Journal of thrombosis and thrombolysis 2008;26(2):79-84.
2008: Emmanouil Brilakis; James A de Lemos; Christopher P Cannon; Stephen D Wiviott; Sabina A Murphy; David A Morrow; Marc S Sabatine; Subhash Banerjee; Michael A Blazing; Robert M Califf; Eugene Braunwald
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
The American journal of cardiology 2008;102(5):552-8.
2008: Marc P Bonaca; David A Morrow
Defining a role for novel biomarkers in acute coronary syndromes.
Clinical chemistry 2008;54(9):1424-31.
2008: Michelle O'Donoghue; David A Morrow
The future of biomarkers in the management of patients with acute coronary syndromes.
Current opinion in cardiology 2008;23(4):309-14.
2008: Jessica L Mega; David A Morrow; James A de Lemos; Satishkumar Mohanavelu; Christopher P Cannon; Marc S Sabatine
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.
Journal of the American College of Cardiology 2008;51(25):2422-9.
2008: David A Morrow; Marc S Sabatine; Marie-Luise Brennan; James A de Lemos; Sabina A Murphy; Christian T Ruff; Nader Rifai; Christopher P Cannon; Stanley L Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.
European heart journal 2008;29(9):1096-102.
2008: Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
Circulation 2008;117(15):1936-44.
2008: Michelle O'Donoghue; David A Morrow; Christopher P Cannon; Wei Guo; Sabina A Murphy; C Michael Gibson; Marc S Sabatine
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.
European heart journal 2008;29(8):984-91.
2008: David A Morrow; Yunmei Wang; Kevin Croce; Masashi Sakuma; Marc S Sabatine; Huiyun Gao; Aruna D Pradhan; Aileen M Healy; Jacqueline Buros; Carolyn H McCabe; Peter Libby; Christopher P Cannon; Eugene Braunwald; Daniel I Simon
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.
American heart journal 2008;155(1):49-55.
2007: Robert W Yeh; Stephen D Wiviott; Robert P Giugliano; David A Morrow; Amy Shui; Jie Qin; Benjamin M Scirica; James E Bradner; Ik-Kyung Jang; C Michael Gibson; Elliott M Antman
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
The American journal of cardiology 2007;100(12):1734-8.
2007: David A Morrow; Elliott M Antman; Sabina A Murphy; Jie Qin; Mikhail Ruda; Sema Guneri; Ashok Joseph Jacob; Andrzej Budaj; Eugene Braunwald
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
American heart journal 2007;154(6):1078-84, 1084.e1.
2007: James A de Lemos; David A Morrow; Michael A Blazing; Petr Jarolim; Stephen D Wiviott; Marc S Sabatine; Robert M Califf; Eugene Braunwald
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
Journal of the American College of Cardiology 2007;50(22):2117-24.
2007: Christian T Ruff; Stephen D Wiviott; David A Morrow; Satishkumar Mohanavelu; Sabina A Murphy; Elliott M Antman; Eugene Braunwald
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
The American journal of medicine 2007;120(11):993-8.
2007: Marc S Sabatine; David A Morrow; Michelle O'Donoghue; Kathleen A Jablonksi; Madeline Murguia Rice; Scott Solomon; Yves Rosenberg; Michael J Domanski; Judith Hsia
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(11):2463-9.
2007: Benjamin M Scirica; David A Morrow; Hanoch Hod; Sabina A Murphy; Luiz Belardinelli; Chester M Hedgepeth; Peter Molhoek; Freek W A Verheugt; Bernard J Gersh; Carolyn H McCabe; Eugene Braunwald
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Circulation 2007;116(15):1647-52.
2007: Benjamin M Scirica; David A Morrow; Christopher P Cannon; James A de Lemos; Sabina Murphy; Marc S Sabatine; Stephen D Wiviott; Nader Rifai; Carolyn H McCabe; Eugene Braunwald
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Clinical chemistry 2007;53(10):1800-7.
2007: Benjamin M Scirica; David A Morrow; Zygmunt Sadowski; Mikhail Ruda; José Carlos Nicolau; Robert P Giugliano; Stephen D Wiviott; Marc S Sabatine; Amy Shui; Elliott M Antman; Eugene Braunwald
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
European heart journal 2007;28(17):2070-6.
2007: Sabina A Murphy; Charles Michael Gibson; David A Morrow; Frans Van de Werf; Ian B Menown; Shaun G Goodman; Kenneth W Mahaffey; Marc Cohen; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
European heart journal 2007;28(17):2077-86.
2007: Stacy E F Melanson; David A Morrow; Petr Jarolim
Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity.
American journal of clinical pathology 2007;128(2):282-6.
2007: Benjamin M Scirica; David A Morrow
Ranolazine in patients with angina and coronary artery disease.
Current cardiology reports 2007;9(4):272-8.
2007: Benjamin A Steinberg; Nazanin Moghbeli; Jacqueline Buros; Mikhail Ruda; Alexander Parkhomenko; B Soma Raju; Armando García-Castillo; Marianna Janion; José Carlos Nicolau; Keith A A Fox; David A Morrow; C Michael Gibson; Elliott M Antman
Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial.
American heart journal 2007;154(1):54-61.
2007: Roberto R Giraldez; José Carlos Nicolau; Ramon Corbalan; Enrique P Gurfinkel; Ursulo Juarez; Jose Lopez-Sendon; Alexander Parkhomenko; Peter Molhoek; Satishkumar Mohanavelu; David A Morrow; Elliott M Antman
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
European heart journal 2007;28(13):1566-73.
2007: Kausik K Ray; David A Morrow; Marc S Sabatine; Amy Shui; Nader Rifai; Christopher P Cannon; Eugene Braunwald
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Circulation 2007;115(24):3071-8.
2007: Marc S Sabatine; David A Morrow; Anthony Dalby; Mathias Pfisterer; Tibor Duris; Jose Lopez-Sendon; Sabina A Murphy; Runlin Gao; Elliott M Antman; Eugene Braunwald
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Journal of the American College of Cardiology 2007;49(23):2256-63.
2007: C Michael Gibson; Sabina A Murphy; Gilles Montalescot; David A Morrow; Diego Ardissino; Marc Cohen; Dietrich C Gulba; Oscar H Kracoff; Basil S. Lewis; Nathan Roguin; Elliott M Antman; Eugene Braunwald
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Journal of the American College of Cardiology 2007;49(23):2238-46.
2007: Jessica L Mega; David A Morrow; Erika Ostör; Maria Dorobantu; Jie Qin; Elliott M Antman; Eugene Braunwald
Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction.
Circulation 2007;115(22):2822-8.
2007: David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Sabina A Murphy; Andrzej Budaj; Sergei Varshavsky; Andrew A Wolff; Allan Michael Skene; Carolyn H McCabe; Eugene Braunwald
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
JAMA : the journal of the American Medical Association 2007;297(16):1775-83.
2007: Kausik K Ray; Christopher P Cannon; David A Morrow; Ajay J Kirtane; Jacqueline Buros; Nader Rifai; Carolyn H McCabe; C Michael Gibson; Eugene Braunwald
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.
European heart journal 2007;28(7):806-13.
2007: Marc S Sabatine; David A Morrow; Kathleen Jablonski; Madeline Murguia Rice; J Wayne Warnica; Michael J Domanski; Judith Hsia; Bernard J Gersh; Nader Rifai; Paul M Ridker; Marc A Pfeffer; Eugene Braunwald
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Circulation 2007;115(12):1528-36.
2007: Marc P Bonaca; Stephen D Wiviott; Marc S Sabatine; Jacqueline Buros; Sabina A Murphy; Benjamin M Scirica; Nader Rifai; Elliott M Antman; David A Morrow
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
The American journal of cardiology 2007;99(3):344-8.
2006: Kausik K Ray; David A Morrow; Amy Shui; Nader Rifai; Christopher P Cannon
Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
The American journal of cardiology 2006;98(7):861-5.
2006: C Michael Gibson; Ajay J Kirtane; David A Morrow; Theresa M Palabrica; Sabina A Murphy; Peter H Stone; Benjamin M Scirica; Lisa K Jennings; Howard C Herrmann; David J Cohen; Carolyn H McCabe; Eugene Braunwald
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
American heart journal 2006;152(4):756-61.
2006: Michelle O'Donoghue; James A de Lemos; David A Morrow; Sabina A Murphy; Jacqueline Buros; Christopher P Cannon; Marc S Sabatine
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Circulation 2006;114(6):550-7.
2006: David A Morrow; James A de Lemos; Marc S Sabatine; Stephen D Wiviott; Michael A Blazing; Amy Shui; Nader Rifai; Robert M Califf; Eugene Braunwald
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
Circulation 2006;114(4):281-8.
2006: Benjamin M Scirica; Marc S Sabatine; David A Morrow; C Michael Gibson; Sabina A Murphy; Stephen D Wiviott; Robert P Giugliano; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
Journal of the American College of Cardiology 2006;48(1):37-42.
2006: Ajay J Kirtane; Gregory Piazza; Sabina A Murphy; Daniela Budiu; David A Morrow; David J Cohen; Eric Peterson; Nasser Lakkis; Howard C Herrmann; Theresa M Palabrica; C Michael Gibson
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.
Journal of the American College of Cardiology 2006;47(12):2374-9.
2006: C Michael Gibson; David A Morrow; Sabina A Murphy; Theresa M Palabrica; Lisa K Jennings; Peter H Stone; Henry H Lui; Thomas Bulle; Nasser Lakkis; Richard Kovach; David J Cohen; Polly Fish; Carolyn H McCabe; Eugene Braunwald
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Journal of the American College of Cardiology 2006;47(12):2364-73.
2006: Benjamin M Scirica; David A Morrow; Christopher P Cannon; Kausik K Ray; Marc S Sabatine; Petr Jarolim; Amy Shui; Carolyn H McCabe; Eugene Braunwald
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Journal of the American College of Cardiology 2006;47(11):2326-31.
2006: David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Allan Michael Skene; Carolyn H McCabe; Eugene Braunwald
Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
American heart journal 2006;151(6):1186.e1-9.
2006: C Michael Gibson; Dimitrios Karmpaliotis; Ioanna Kosmidou; Sabina A Murphy; Ajay J Kirtane; Daniela Budiu; Kausik K Ray; Howard C Herrmann; Nasser Lakkis; Richard Kovach; William J French; James Blankenship; Henry H Lui; Theresa M Palabrica; Lisa K Jennings; David J Cohen; David A Morrow
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.
The American journal of cardiology 2006;97(10):1473-7.
2006: Benjamin M Scirica; David A Morrow
Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out.
Circulation 2006;113(17):2128-34; discussion 2151.
2006: Thomas W Wallace; Shuaib M Abdullah; Mark H Drazner; Sandeep R Das; Amit Khera; Darren K McGuire; Frank H Wians; Marc S Sabatine; David A Morrow; James A de Lemos
Prevalence and determinants of troponin T elevation in the general population.
Circulation 2006;113(16):1958-65.
2006: Stephen D Wiviott; David A Morrow; Paul D Frederick; Elliott M Antman; Eugene Braunwald
Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction.
Journal of the American College of Cardiology 2006;47(8):1553-8.
2006: Michelle O'Donoghue; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Circulation 2006;113(14):1745-52.
2006: Elliott M Antman; David A Morrow; Carolyn H McCabe; Sabina A Murphy; Mikhail Ruda; Zygmunt Sadowski; Andrzej Budaj; Jose L López-Sendón; Sema Guneri; Frank Jiang; Harvey D White; Keith A A Fox; Eugene Braunwald
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
The New England journal of medicine 2006;354(14):1477-88.
2006: Shaheeda Ahmed; Elliott M Antman; Sabina A Murphy; Robert P Giugliano; Christopher P Cannon; Harvey White; David A Morrow; Eugene Braunwald
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials).
Journal of thrombosis and thrombolysis 2006;21(2):119-29.
2006: Benjamin M Scirica; David A Morrow
Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI.
Current treatment options in cardiovascular medicine 2006;8(1):13-21.
2006: Christian T Ruff; Robert Giugliano; David A Morrow
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease.
Future cardiology 2006;2(1):85-91.
2006: Marc S Sabatine; David A Morrow; Carolyn H McCabe; Elliott M Antman; C Michael Gibson; Christopher P Cannon
Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.
American heart journal 2006;151(1):25-31.
2005: Marc S Sabatine; Emerson Liu; David A Morrow; Eric Heller; Robert McCarroll; Roger Wiegand; Gabriel F Berriz; Frederick P Roth; Robert E Gerszten
Metabolomic identification of novel biomarkers of myocardial ischemia.
Circulation 2005;112(25):3868-75.
2005: Marc S Sabatine; David A Morrow; Gilles Montalescot; Mikael Dellborg; Jose L Leiva-Pons; Mátyás Keltai; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Circulation 2005;112(25):3846-54.
2005: Shuaib M Abdullah; Amit Khera; Sandeep R Das; Harold G Stanek; Russell M Canham; Anne K Chung; David A Morrow; Mark H Drazner; Darren K McGuire; James A de Lemos
Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study).
The American journal of cardiology 2005;96(9):1284-9.
2005: Kausik K Ray; Christopher P Cannon; Richard Cairns; David A Morrow; Nader Rifai; Ajay J Kirtane; Carolyn H McCabe; Allan Michael Skene; C Michael Gibson; Paul M Ridker; Eugene Braunwald
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Journal of the American College of Cardiology 2005;46(8):1417-24.
2005: Stephen D Wiviott; Christopher P Cannon; David A Morrow; Kausik K Ray; Marc A Pfeffer; Eugene Braunwald
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Journal of the American College of Cardiology 2005;46(8):1411-6.
2005: James A de Lemos; Andreas Zirlik; Uwe Schönbeck; Nerea Varo; Sabina A Murphy; Amit Khera; Darren K McGuire; Greg Stanek; Hao S Lo; Rebecca Nuzzo; David A Morrow; ronald peshock; Peter Libby
Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(10):2192-6.
2005: Paul M Ridker; David A Morrow; Lynda M Rose; Nader Rifai; Christopher P Cannon; Eugene Braunwald
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Journal of the American College of Cardiology 2005;45(10):1644-8.
2005: Jessica L Mega; David A Morrow; Marc S Sabatine; Xue-Qiao Zhao; Steven M Snapinn; Peter M DiBattiste; C Michael Gibson; Elliott M Antman; Eugene Braunwald; Pierre Théroux
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
American heart journal 2005;149(5):846-50.
2005: Marc S Sabatine; David A Morrow; Robert P Giugliano; Paul B J Burton; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Eugene Braunwald
Association of hemoglobin levels with clinical outcomes in acute coronary syndromes.
Circulation 2005;111(16):2042-9.
2005: David A Morrow; Sabina A Murphy; Carolyn H McCabe; Nigel Mackman; Hing C Wong; Elliott M Antman
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial.
European heart journal 2005;26(7):682-8.
2005: Marc S Sabatine; Gavin J Blake; Mark H Drazner; David A Morrow; Benjamin M Scirica; Sabina A Murphy; Carolyn H McCabe; William S Weintraub; C Michael Gibson; Christopher P Cannon
Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment.
Circulation 2005;111(10):1217-24.
2005: Kausik K Ray; David A Morrow; C Michael Gibson; Sabina Murphy; Elliott M Antman; Eugene Braunwald
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
European heart journal 2005;26(5):440-6.
2004: Marc S Sabatine; David A Morrow; James A de Lemos; Torbjørn Omland; Milind Y Desai; Milenko J Tanasijevic; Christian Hall; Carolyn H McCabe; Eugene Braunwald
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.
Journal of the American College of Cardiology 2004;44(10):1988-95.
2004: Rajat Deo; Amit Khera; Darren K McGuire; Sabina A Murphy; Januario de P Meo Neto; David A Morrow; James A de Lemos
Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis.
Journal of the American College of Cardiology 2004;44(9):1812-8.
2004: Benjamin M Scirica; David A Morrow
Troponins in acute coronary syndromes.
Progress in cardiovascular diseases 2004;47(3):177-88.
2004: C Michael Gibson; Raphaelle L Dumaine; Eli V Gelfand; Sabina A Murphy; David A Morrow; Stephen D Wiviott; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials.
European heart journal 2004;25(22):1998-2005.
2004: Dimitrios Karmpaliotis; Minang P Turakhia; Ajay J Kirtane; Sabina A Murphy; Ioanna Kosmidou; David A Morrow; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald; C Michael Gibson
Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction.
The American journal of cardiology 2004;94(9):1113-7.
2004: David A Morrow; Marc S Sabatine; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; Pierre Theroux
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
The American journal of cardiology 2004;94(6):774-6.
2004: Stephen D Wiviott; David A Morrow; Paul D Frederick; Robert P Giugliano; C Michael Gibson; Carolyn H McCabe; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2004;44(4):783-9.
2004: Stephen D Wiviott; James A de Lemos; David A Morrow
Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes.
Clinica chimica acta; international journal of clinical chemistry 2004;346(2):119-28.
2004: Jessica L Mega; David A Morrow; James A De Lemos; Marc S Sabatine; Sabina A Murphy; Nader Rifai; C Michael Gibson; Elliott M Antman; Eugene Braunwald
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
Journal of the American College of Cardiology 2004;44(2):335-9.
2004: David A Morrow; Elliott M Antman; Sabina A Murphy; Susan F Assmann; Robert P Giugliano; Christopher P Cannon; C Michael Gibson; Carolyn H McCabe; Hal V Barron; Frans Van de Werf; Eugene Braunwald
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies.
European heart journal 2004;25(13):1139-45.
2004: Robert P Giugliano; Marc S Sabatine; C Michael Gibson; Matthew T Roe; Robert A Harrington; Sabina A Murphy; David A Morrow; Elliott M Antman; Eugene Braunwald
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
The American journal of cardiology 2004;93(11):1362-7, A5-6.
2004: Masahisa Shimpo; David A Morrow; Ellen O Weinberg; Marc S Sabatine; Sabina A Murphy; Elliott M Antman; Richard T Lee
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.
Circulation 2004;109(18):2186-90.
2004: C Michael Gibson; Juhana Karha; Sabina A Murphy; James A de Lemos; David A Morrow; Robert P Giugliano; Matthew T Roe; Robert A Harrington; Christopher P Cannon; Elliott M Antman; Robert M Califf; Eugene Braunwald
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
Journal of the American College of Cardiology 2004;43(7):1170-6.
2004: Marc S Sabatine; David A Morrow; Robert P Giugliano; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; William S Weintraub; Carolyn H McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Circulation 2004;109(7):874-80.
2004: Stephen D Wiviott; Christopher P Cannon; David A Morrow; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Marc S Sabatine; Nader Rifai; Robert P Giugliano; Peter M DiBattiste; Laura A Demopoulos; Elliott M Antman; Eugene Braunwald
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.
Circulation 2004;109(5):580-6.
2003: C Michael Gibson; Duane S Pinto; Sabina A Murphy; David A Morrow; Hans-Peter Hobbach; Stephen D Wiviott; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.
Journal of the American College of Cardiology 2003;42(9):1535-43.
2003: Benjamin M Scirica; David A Morrow
Troponins in acute coronary syndromes.
Seminars in vascular medicine 2003;3(4):363-74.
2003: Nerea Varo; James A de Lemos; Peter Libby; David A Morrow; Sabina A Murphy; Rebecca Nuzzo; C Michael Gibson; Christopher P Cannon; Eugene Braunwald; Uwe Schönbeck
Soluble CD40L: risk prediction after acute coronary syndromes.
Circulation 2003;108(9):1049-52.
2003: C Michael Gibson; Juhana Karha; Sabina A Murphy; David James; David A Morrow; Christopher P Cannon; Robert P Giugliano; Elliott M Antman; Eugene Braunwald
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.
Journal of the American College of Cardiology 2003;42(1):7-16.
2003: David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.
Journal of the American College of Cardiology 2003;41(8):1264-72.
2003: James A de Lemos; David A Morrow
Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes.
Reviews in cardiovascular medicine 2003;4 Suppl 4():S37-46.
2002: Marc S Sabatine; David A Morrow; Christopher P Cannon; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; Eugene Braunwald; C Michael Gibson
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.
Journal of the American College of Cardiology 2002;40(10):1761-8.
2002: Howard A Cooper; James A de Lemos; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Elliott M Antman; Eugene Braunwald
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration.
American heart journal 2002;144(5):790-5.
2002: Benjamin M Scirica; Christopher P Cannon; Elliott M Antman; Sabina A Murphy; David A Morrow; Marc S Sabatine; Carolyn H McCabe; C Michael Gibson; Eugene Braunwald
Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry.
The American journal of cardiology 2002;90(3):303-5.
2002: James A de Lemos; David A Morrow; C Michael Gibson; Sabina A Murphy; Marc S Sabatine; Nader Rifai; Carolyn H McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies.
Journal of the American College of Cardiology 2002;40(2):238-44.
2002: Graham C Wong; David A Morrow; Sabina Murphy; Nicole Kraimer; Rupal Pai; David James; Debbie H Robertson; Laura A Demopoulos; Peter M DiBattiste; Christopher P Cannon; C Michael Gibson
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.
Circulation 2002;106(2):202-7.
2002: David A Morrow; Elliott M Antman; Assaad Sayah; Kristin C Schuhwerk; Robert P Giugliano; James A deLemos; Michael Waller; Sidney A Cohen; Donald G Rosenberg; Sally S Cutler; Carolyn H McCabe; Ron M Walls; Eugene Braunwald
Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.
Journal of the American College of Cardiology 2002;40(1):71-7.
2002: Marc S Sabatine; Carolyn H McCabe; David A Morrow; Robert P Giugliano; James A de Lemos; Marc Cohen; Elliott M Antman; Eugene Braunwald
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.
American heart journal 2002;143(6):966-70.
2002: Marc S Sabatine; David A Morrow; James A de Lemos; C Michael Gibson; Sabina A Murphy; Nader Rifai; Carolyn McCabe; Elliott M Antman; Christopher P Cannon; Eugene Braunwald
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
Circulation 2002;105(15):1760-3.
2002: David A Morrow; Elliott M Antman; Steven M Snapinn; Carolyn H McCabe; Pierre Theroux; Eugene Braunwald
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
European heart journal 2002;23(3):223-9.
2001: David A Morrow; Christopher P Cannon; Nader Rifai; MJ Frey; R Vicari; Nasser Lakkis; Debbie H Robertson; D A Hille; Paul T DeLucca; Peter M DiBattiste; Laura A Demopoulos; William S Weintraub; Eugene Braunwald
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
JAMA : the journal of the American Medical Association 2001;286(19):2405-12.
2001: David A Morrow; Elliott M Antman; Robert P Giugliano; Richard Cairns; A Charlesworth; Sabina A Murphy; James A de Lemos; Carolyn H McCabe; Eugene Braunwald
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy.
Lancet 2001;358(9293):1571-5.
2001: J A de Lemos; David A Morrow; J H Bentley; T Omland; Marc S Sabatine; Carolyn H McCabe; C Hall; Christopher P Cannon; Eugene Braunwald
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
The New England journal of medicine 2001;345(14):1014-21.
2001: David A Morrow; Elliott M Antman; L Parsons; James A de Lemos; Christopher P Cannon; Robert P Giugliano; Carolyn H McCabe; H V Barron; Eugene Braunwald
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3.
JAMA : the journal of the American Medical Association 2001;286(11):1356-9.
2001: James A de Lemos; David A Morrow; C Michael Gibson; Sabina A Murphy; Nader Rifai; M Tanasijevic; Robert P Giugliano; Kristin C Schuhwerk; Carolyn H McCabe; C P Cannon; Elliott M Antman; Eugene Braunwald
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy.
The American journal of cardiology 2001;88(4):353-8.
2001: James A de Lemos; C Michael Gibson; Elliott M Antman; Sabina A Murphy; David A Morrow; Kristin C Schuhwerk; M Schweiger; P Coussement; Frans Van de Werf; Eugene Braunwald
Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial.
American heart journal 2001;141(4):592-8.
2001: David A Morrow
Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications.
Cardiovascular toxicology 2001;1(2):105-10.
2000: James A de Lemos; Elliott M Antman; Robert P Giugliano; David A Morrow; Carolyn H McCabe; S S Cutler; A Charlesworth; R Schröder; Eugene Braunwald
Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.
The American journal of cardiology 2000;86(11):1235-7, A5.
2000: David A Morrow; Elliott M Antman; Milenko J Tanasijevic; Nader Rifai; James A de Lemos; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.
Journal of the American College of Cardiology 2000;36(6):1812-7.
2000: David A Morrow; Elliott M Antman; A Charlesworth; Richard Cairns; Sabina A Murphy; James A de Lemos; Robert P Giugliano; Carolyn H McCabe; Eugene Braunwald
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.
Circulation 2000;102(17):2031-7.
2000: James A de Lemos; Elliott M Antman; Robert P Giugliano; David A Morrow; Carolyn H McCabe; A Charlesworth; R Schröder; Eugene Braunwald
Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram.
American heart journal 2000;140(3):373-8.
2000: James A de Lemos; Elliott M Antman; David A Morrow; J Llevadot; Robert P Giugliano; SA Coulter; Kristin C Schuhwerk; S Arslanian; Carolyn H McCabe; C Michael Gibson; Nader Rifai
Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy.
Clinica chimica acta; international journal of clinical chemistry 2000;298(1-2):85-97.
2000: David A Morrow; Nader Rifai; Milenko J Tanasijevic; DR Wybenga; James A de Lemos; Elliott M Antman
Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy.
Clinical chemistry 2000;46(4):453-60.
2000: David A Morrow; Nader Rifai; Elliott M Antman; D L Weiner; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy.
Journal of the American College of Cardiology 2000;35(2):358-62.
1998: David A Morrow; Nader Rifai; Elliott M Antman; D L Weiner; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
Journal of the American College of Cardiology 1998;31(7):1460-5.